General Archives - Gilde Healthcare


Gilde Healthcare invests in German precision surgical instruments contract manufacturer Koscher & Würtz

The acquisition of Koscher & Würtz represents a major step for Gilde Healthcare in forming a market leading instrument contract manufacturing group, following its initial investment in Chr. Diener, less than 18 months ago. Koscher & Würtz (K&W) will join as a group company next to Chr. Diener, together employing about 300 highly qualified staff members. By joining forces, K&W...
20 november 2023

Gilde Healthcare sluit nieuw Venture&Growth fonds op €740 miljoen hard cap

test Gilde Healthcare Venture&Growth VI sluit op hard cap met €740 miljoen aan commitments van een gebalanceerde mix van internationale investeerders Gilde Healthcare investeert in snelgroeiende bedrijven die betere zorg tegen lagere kosten mogelijk maken, ondersteund door de recent aangestelde Impact Council In drie jaar tijd haalt Gilde Healthcare €1,7 miljard op, verdeeld over drie fondsen          […]

Gilde Healthcare company SpliceBio enters $216 million Gene Therapy collaboration with Spark Therapeutics

test SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal disease SpliceBio, a genetic medicines company harnessing Protein Splicing to develop the next generation of […]

Gilde Healthcare company AM-Pharma announces positive clinical data from Phase 1b study evaluating ilofotase alfa in hypophosphatasia patients

AM-Pharma B.V. today announced positive clinical results from the Phase 1b study evaluating the company’s proprietary recombinant alkaline phosphatase, ilofotase alfa, as potential enzyme replacement therapy in adult hypophosphatasia (HPP) patients. HPP is an inherited metabolic disease, characterized by low activity of tissue non-specific alkaline phosphatase (TNAP),...

Gilde Healthcare company Amphista Therapeutics Achieves First Milestone in Second Discovery Programme with Bristol Myers Squibb

Amphista Therapeutics (“the Company” or “Amphista”), a leader in next generation targeted protein degradation (TPD) approaches, today announces it has achieved the first milestone in the second active discovery programme under its strategic collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY), triggering a payment for...

Gilde Healthcare company AM-Pharma announces updated clinical development strategy

Advancing ilofotase alfa into a Phase 2 study for lead indication cardiac surgery-associated renal damage Phase 1b study of ilofotase alfa as enzyme replacement therapy in hypophosphatasia patients being finalized, results to be announced before end of 2023 Juliane Bernholz, AM-Pharma’s Chief Operating Officer since 2019, succeeds...

Gilde Healthcare company Moximed reports treatment of first commercial patients post FDA approval

Implantable shock absorber (ISA) relieves pain and improves function in people ineligible for, or unwilling to undergo, joint replacement Multiple surgeons from multiple U.S. centers treat patients with knee osteoarthritis

Gilde Healthcare company Withings launches its next-generation scanwatch with enhanced sensors to monitor additional health metrics 24/7

Withings introduces the hybrid watch that watches your health day and night with new capabilities to monitor body temperature 24/7, heart rate variability, respiratory rate and female menstrual cycles

Volta Medical Announces Initiation of RESTART Clinical Trial for Treatment of Repeat Atrial Fibrillation

Interventional study to evaluate long term outcomes of Volta’s AI solution-supported ablation in recurrent-AF patients who failed previous ablation International, multi-center trial at 21 sites with results expected in 2025 Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologists in treating...
These were all messages